Year-over-year earnings per share growth for the last twelve months: MiNK Therapeutics, Inc. (INKT)

minktherapeutics.com (INKT) - corporate logo

MiNK Therapeutics, Inc. (INKT) results are independent of economic cycles, as demand for oncology therapy remains stable. The quarterly EPS growth trajectory visualizes this disconnect between the market and reality, where the value of 22.70 corresponds to the current metric. A lack of sales leads to constant cash burn, and pricing power will only emerge following FDA approval.

MiNK Therapeutics Inc. (INKT) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for minktherapeutics.com (INKT)

Comprehensive company analysis:MiNK Therapeutics Inc., INKT
Manufactured product of MiNK Therapeutics, Inc.

This indicator measures the dynamics of net earnings per share, allowing for an assessment of cost management efficiency and real business margins during periods of inflationary pressure. By analyzing the volatility of the quarterly EPS, an investor can determine the ability of MiNK Therapeutics, Inc. (INKT) to fund the development of universal iNKT cells for mass cancer treatment without compromising financial stability in the face of regulatory risks.

Competitors of MiNK Therapeutics, Inc.

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months januxrx.com|Year-over-year net earnings per share growth for the last 12 months arcusbio.com (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc (ZYME)|Year-over-year net earnings per share growth for the last 12 months Tango Pharma TNGX|Iovance Biotherapeutics Inc - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics Biotechnologies IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (compasstherapeutics.com) - Year-over-year earnings per share growth for the last 12 months|Replimune Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Lyell Immunopharma Inc (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months ALX Oncology Holdings Inc.|CUE: Quarterly EPS earnings growth|PDS Biotech - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIA Biotech|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Inc - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Earnings per share growth in annualized terms for the last twelve months|Intensity Therapeutics Inc - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months senseibio.com SNSE|TOVX: Quarterly EPS earnings growth|Gritstone bio Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KA|Year-over-year earnings per share growth for the last 12 months NEXI (NexImmune, Inc.)|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics Corporation (TSBX)|Year-over-year net earnings per share growth for the last 12 months Vaccinex VCNX|Year-over-year earnings per share growth for the last twelve months harpoontx.com HARP